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Short Communication
The effect of adjuvant cyclophosphamide or tamoxifen on
the numbers of lymphocytes bearing T cell or NK cell
markers
C.R. Sheard, F. Reilly, D.E.H. Tee, D. Vergani, D. Lowe, M. Baum
& A.E.P. Cameron
Departments ofImmunology and Surgery, King's College School ofMedicine and Dentistry,
London SE5 8RX, UK.
Many women with 'early' breast cancer now receive
systemic adjuvant therapy along with surgical
treatment because occult micrometastases may
already be present.
Any benefits accruing from adjuvant therapy are
attributed to direct effects on the cancer cells, but it
is also possible that such treatments migh subtly
modify any host resistance to the tumour.
To investigate some effects of adjuvant systemic
therapy on the patient we have performed a pilot
study of changes in peripheral blood lymphocyte
population following a short course of
cyclophosphamide and/or tamoxifen.
Patients from three centres participating in the
Cancer Research Campaign adjuvant trial were
recruited into the study. All were clinically Stage I
and II breast cancer patients without previous or
synchronous malignancy and were on no other
treatment. Routine local surgery was performed
and the patients were then randomised into one of
four groups. Group 1 received no adjuvant
treatment (8 patients); Group 2 was started on
tamoxifen - 10mg twice daily within 24h of
surgery (14 patients); Group 3 received cyclo-
phosphamide - 5mg kg-1day - i.v. over a 6 day
period beginning on the first postoperative day (6
patients); Group 4 received both cyclophosphamide
and tamoxifen (13 patients).
Blood samples (30ml) were taken from each
patient on day 0, (the morning preceding surgery),
and on day 8.
Total white cell counts were performed by
Coulter counter and differential counts by
microscopy of stained smears.
Peripheral blood mononuclear cells were isolated
by density gradient centrifugation on Ficoll-
Hypaque (Pharmacia) (Boyum, 1968).
Lymphocyte subsets were enumerated using the
monoclonal antibodies Leu 4, Leu 3, Leu 2 and
Leu 11 (Beckton & Dickinson). Anti-Leu 4
identifies peripheral T-lymphocytes, anti-Leu 3
identifies the helper inducer subset of T cells, anti-
Leu 2 identifies the suppressor/cytotoxic subset and
anti-Leu 11 reacts with a population of mono-
nuclear cells thought to perform natural killing
(NK). An indirect technique using a second
fluorescence-conjugated rabbit anti-mouse antibody
(Dako-Patts) was employed as follows: aliquots of
50,ul of cells were incubated with saturating
amounts of monoclonal antibody for 30min at 4°C.
After washing, the cells were then incubated with
fluorescein-labelled rabbit anti-mouse antibody for
30min at 4°C. The cells were washed in Hank's
buffered saline containing 0.1% sodium azide and
finally resuspended in 1% paraformaldehyde in
Hank's buffered saline. The proportion of
fluorescein stained lymphocytes was determined
using a fluorescence activated cell analyser (FACS
Analyser - Becton & Dickinson), equipped for
simultaneous measurement of electronic cell volume
and two colour fluorescence. (There was no facility
for wide-angle light-scatter to control for granulo-
cytes but previous experience suggested that there
would be <2% contamination). The volume gates
were set to exclude monocytes and 1000 cells were
counted. The number of cells per 10 -9 litres of
peripheral blood in each subset was calculated by
multiplying the percentage of stained cells by the
total number of lymphocytes, derived from the total
and differential white cell counts.
A paired t-test was used to assess changes in
peripheral blood lymphocyte composition between
day 0 and day 8 for each treatment group.
A 2-way analysis of variance was used to
compare the changes in lymphocyte composition in
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Table I Mean numbers of lymphocytes at day 0 and day 8 and their mean differences.a
Group I Group 4
No Group 2 Group 3 Tamoxifen and
chemotherapy Tamoxifen Cyclophosphamide cyclophosphamide
(8 patients) (14 patients) (6 patients) (13 patients)
DayO Day 8 DayO Day 8 DayO Day 8 DayO Day 8
Lymphocytes Mean 2.62b 2.68 2.16 2.66 3.30 2.03 2.18 1.78
Mean diff.+s.e. 0.06+0.81 0.50+0.31 -1.27+0.62 -0.40+0.20
(day 8-day 0) P=0.94 P=0.14 P=0.09 P=0.06
T lymphocytes Mean 1.48 1.27 1.37 1.66 1.98 1.30 1.34 1.06
Mean diff. +s.e. -0.21+0.40 0.29+0.18 -0.66+0.38 -0.27+0.12
(day 8-dayO) P=0.62 P=0.12 P=0.14 P=0.04
T helper/inducer Mean 1.02 1.04 0.81 1.04 1.45 1.00 0.87 0.72
(Leu 3) Mean diff. +s.e. 0.02+0.35 0.25+0.12 -0.46+0.30 -0.15+0.08
(day 8-day 0) P=0.95 P=0.08 P=0.19 P=0.09
T suppressor Mean 0.61 0.41 0.54 0.61 0.66 0.39 0.53 0.42
cytotoxic Mean diff. +s.e. -0.20+0.11 0.07+0.08 -0.26+0.11 -0.11+0.07
(Leu 2) (day 8-day 0) P=0.11 P=0.40 P=0.06 P=0.12
NK lymphocytes Mean 0.50 0.40 0.35 0.47 0.48 0.16 0.39 0.29
(Leu 11) Mean diff. +s.e. -0.10+0.11 0.13+0.08 -0.32+0.16 -0.10+0.07
(day 8-day 0) P=0.36 P=0.14 P=0.11 P=0.17
aAnalysed by paired t-test. bUnits: No. of cells 10-9 litres peripheral blood.
the groups of patients receiving chemotherapy with
those having only surgery and to indicate whether
cyclophosphamide and tamoxifen were acting
independently or interacting to give a combined
effect.
The results were analysed with the aid of the
Statistical Package for the Social Sciences (SPSS
Inc. Chicago Ill).
The numbers of peripheral blood lymphocytes
and their subsets are shown in Table I. The mean
change for each group between the day of surgery,
day 0, and day 8 is also given.
Patients who received no adjuvant therapy
(Group 1) showed no significant change in the
lymphocyte count. T-suppressor/cytotoxic cells were
slightly reduced in number, but the others were
unchanged.
The patients receiving tamoxifen only (Group 2)
showed more marked changes. The mean lympho-
cyte count had increased as had the total T cells.
There was a rise in T helper/inducer cells with a
less marked increase in T suppressor/cytotoxic cells.
NK cells were also increased.
Conversely patients receiving cyclophosphamide
(Group 3) had a reduced lymphocyte count
affecting all subsets. Group 4 patients receiving
both cyclophosphamide and tamoxifen also showed
reductions in lymphocyte and subset numbers,
though smaller than those of Group 3. The group
mean changes were then compared by a two-way
analysis of variance. The outome of this analysis is
shown graphically (Figure 1 a-e).
This 'two-way' analysis allows for different
sources of variation to be accounted for. The effects
of each drug may be significant or insignificant and
these are estimated independently. If the effects of
each drug were simply additive (i.e. with no
interaction effect) and if no random experimental
error were present, the graphs would be true
parallelograms. The high probability values (P)
reported for the interaction of cyclophosphamide
and tamoxifen indicate an independent effect of the
two drugs. Furthermore the low probability values
for the independent effects of cyclophosphamide
and tamoxifen, tend to support a genuine effect. It
can be seen that for each cell type the two drugs
act in opposition: tamoxifen increases the numbers
of cells bearing T and NK markers in the
peripheral blood while cyclophosphamide reduces
them.
These results indicate that surgery alone had little
effect on the total lymphocyte count or upon T cell
subsets in the eight control patients, with only a
minor reduction in the T-suppressor cells in the day
8 sample. Surgery per se may cause a little immuno-
suppression; e.g. after cholecystectomy T-helper:T-
suppressor cell ratios decreased on the first post-
operative day but returned to normal by the fifth
day (Hansbrough et al., 1984). Therefore most of
the changes we observed on the eighth day in theADJUVANT THERAPY AND LYMPHOCYTE NUMBERS 707
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Figure 1 Mean differences in lymphocyte numbers.
(a) LYMPHOCYTES
Main effects CY P=0.02
TMX P=0.18
Interaction CY/TMX P=0.65
(b) T-LYMPHOCYTES
Main effects CY P=0.03
TMX P=0.08
Interaction CY/TMX P=0.83
(c) T HELPER/INDUCER LYMPHOCYTES
Main effects CY P=0.04
TMX P=0.22
Interaction CY/TMX P=0.81
(d) T SUPPRESSOR/CYTOTOXIC LYMPHOCYTES
Main effects CY P=0.12
TMX P=0.02
Interaction CY/TMX P=0.54
(e) NK CELLS
Main effects CY P=0.02
TMX P=0.03
Interaction CY/TMX P=0.98
CY - cyclophosphamide
TMX - tamoxifen
Group 1- no chemotherapy
Group 2- TMX
Group 3- CY
Group 4- TMX and CY708 C.R. SHEARD et al.
adjuvant-treated patients will have been due to the
adjuvant treatment rather than surgery: the effects
of surgery are further excluded by the analysis of
variance between the groups.
Cyclophosphamide treatment caused a fall in the
total lymphocyte count, but might have had a
preferential effect on specific subsets. Nearly 20
years ago it was found that a 5 day course of
cyclophosphamide in guinea pigs augmented cell-
mediated delayed hypersensitivity reactions
(Maguire & Ettore, 1967). Subsequent animal work
has shown that T cell mediated immune responses
are under the control of cyclophosphamide-sensitive
suppressor cells (Rollinghof et al., 1977). A
preferential effect of cyclophosphamide upon such
cells would augment cellular immunity. However,
few studies have been performed in humans. In
vitro studies suggest that in man T-suppressor cells
are cyclophosphamide-sensitive (Ozer et al., 1982).
Two studies have shown that in patients with
advanced cancer a single dose of cyclophosphamide
can increase cutaneous cell-mediated reactions (Berd
et al., 1982; Berd et al., 1984), and one study reports
that cyclophosphamide produces 'favourable'
changes in the T-helper:T-suppressor ratio (Bast
et al., 1983). Our results show that all subsets were
reduced in number and suggest that T-helper/inducer
cells were more affected than T-suppressor/cytotoxic.
Our results may differ from these other reports
for several reasons: Firstly the above studies were
performed on patients whose immune responses
were suppressed by advanced cancer whilst our
patients with early cancer probably do not differ
from the normal population (McCluskey et al.,
1983). Secondly, the phenomenon of enhanced
immunity is dependent both on the dose and timing
of cyclophosphamide. The above studies used a
single large dose of cyclophosphamide (up to
25mgkg-1) whereas adjuvant treatment employs
less drug for longer (5mgkg- I day-1 for 6 days).
The results obtained with tamoxifen were
unexpected. The absolute numbers of lymphocytes,
T cells, T-helper/inducer and NK cells increased,
with a less remarkable change in the T-
suppressor/cytotoxic cells. The analysis of variance
suggests that tamoxifen may have opposed the
decrease in T-suppressor/cytotoxic cells caused by
surgery alone, but the overall effect was to produce
an increase in all classes of lymphocyte analysed in
the peripheral circulation.
Further evidence for a stimulant effect produced
by tamoxifen is seen, in the group receiving
combination therapy. Although the combined
treatment did cause lymphodepletion, the inter-
group analysis suggests that tamoxifen opposed the
effect of cyclophosphamide (Figure 1). Interestingly
it has recently been shown that women receiving
tamoxifen for breast cancer showed significantly
elevated NK activity when compared to patients on
all other chemotherapy, including cyclophosph-
amide (Brenner et al., 1985).
Our study confirms this observation in terms of
NK cell numbers but also suggests that other
populations of lymphocytes in peripheral blood are
increased. It is difficult to assess the significance of
this finding. A 2 year course of adjuvant tamoxifen
favourably influences the course of early breast
cancer, but surprisingly perhaps the effect does not
correlate with menopausal or node status or indeed
with the level of oestrogen receptors in the tumour
(Baum, 1985). It is possible that other mechanisms
may be involved in addition to any antioestrogen
effect. We have observed changes in cell
populations, but whether these are of importance
can only be assessed by further studies which
should include functional assays of the T cell and
NK cell systems.
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